Details of the Drug

General Information of Drug (ID: DM6CLBN)

• Drug Name: Danaparoid
• Synonyms: Orgaran (TN)

Indication

Disease Entry	ICD 11	Status	REF
Deep venous clot	BD71	Approved	[1]

• Therapeutic Class: Anticoagulants
• ADMET Property:
  Bioavailability: The bioavailability of drug is 60% [2]
  Clearance: The total plasma clearance of drug is 0.36 L/h [3]
  Elimination: Renal excretion is the main route of elimination, accounting for approximately 40-50% of the total clearance of antifactor Xa activity following intravenous administration of danaparoid [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 19.2 - 24.5 hours [3]
  Metabolism: The drug is metabolized via the hepatic [3]
  Vd: The volume of distribution (Vd) of drug is 9.1 L [3]
• Cross-matching ID:
  DrugBank ID: DB06754
  TTD ID: D0P3SY

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor Xa (F10)	TTCIHJA	FA10_HUMAN	Inhibitor	[4]

Molecular Expression Atlas of This Drug

• The Studied Disease: Deep venous clot
• ICD Disease Classification: BD71

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Coagulation factor Xa (F10)	DTT	F10	4.84E-02	-0.28	-0.9

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Danaparoid (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Danaparoid and Levomilnacipran.	Chronic pain [MG30]	[5]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Danaparoid and Regorafenib.	Colorectal cancer [2B91]	[6]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Danaparoid and Ardeparin.	Coronary thrombosis [BA43]	[7]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Danaparoid and Vortioxetine.	Depression [6A70-6A7Z]	[5]
Apigenin	DMI3491	Minor	Increased risk of bleeding by the combination of Danaparoid and Apigenin.	Discovery agent [N.A.]	[8]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Danaparoid and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[6]
Aliskiren	DM1BV7W	Moderate	Increased risk of hyperkalemia by the combination of Danaparoid and Aliskiren.	Hypertension [BA00-BA04]	[9]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Danaparoid and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[10]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Danaparoid and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[11]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Danaparoid and Ibrutinib.	Mature B-cell lymphoma [2A85]	[12]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Danaparoid and Ponatinib.	Mature B-cell lymphoma [2A85]	[13]
Fedratinib	DM4ZBK6	Major	Increased risk of bleeding by the combination of Danaparoid and Fedratinib.	Myeloproliferative neoplasm [2A20]	[14]
Ruxolitinib	DM7Q98D	Major	Increased risk of bleeding by the combination of Danaparoid and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[7]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Danaparoid and Vorapaxar.	Myocardial infarction [BA41-BA43]	[7]
Nepafenac	DMYK490	Moderate	Increased risk of bleeding by the combination of Danaparoid and Nepafenac.	Osteoarthritis [FA00-FA05]	[15]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Danaparoid and MK-4827.	Ovarian cancer [2C73]	[6]
Choline salicylate	DM8P137	Moderate	Increased risk of bleeding by the combination of Danaparoid and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[16]
Curcumin	DMQPH29	Minor	Increased risk of bleeding by the combination of Danaparoid and Curcumin.	Solid tumour/cancer [2A00-2F9Z]	[17]
Brilinta	DMBR01X	Major	Increased risk of bleeding by the combination of Danaparoid and Brilinta.	Thrombosis [DB61-GB90]	[7]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Danaparoid and Cabozantinib.	Thyroid cancer [2D10]	[18]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Danaparoid and Betrixaban.	Venous thromboembolism [BD72]	[14]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6804).
• [2] Somogyi A, Gugler R: Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet. 1983 Nov-Dec;8(6):463-95. doi: 10.2165/00003088-198308060-00001.
• [3] Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs. 1997 Dec;54(6):903-24.
• [4] Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
• [5] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
• [6] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [7] Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
• [8] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
• [9] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [10] Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
• [11] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [12] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [13] Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [14] Product Information. Fragmin (dalteparin). Pharmacia and Upjohn, Kalamazoo, MI.
• [15] Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
• [16] Fausa O "Salicylate-induced hypoprothrombinemia: a report of four cases." Acta Med Scand 188 (1970): 403-8. [PMID: 5490567]
• [17] Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
• [18] Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.